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from parents whose children have life-limiting conditions and enrolled in Florida’s 
State Title V Program. Telephone surveys were conducted using 266 random parents 
between November 2007 and April 2008. The Wake Forest Physician Trust Scale was
used to measure parents’ trust in physicians. The Decisional Conﬂ ict Scale (DCS) was 
used to measure conﬂ icts in decision making, e.g., uncertainty and uninformed and 
ineffective choices. The total score of DCS to represent the magnitude of decisional
conﬂ icts. We conducted multivariate analyses to test whether parent’s age, race, educa-
tion, personality traits, and parent-report of children’s health status were associated
with physician trust and decisional conﬂ icts. We tested whether greater trust in physi-
cians was associated with less decisional conﬂ icts after controlling for parental char-
acteristics. RESULTS: Parents with less than a high school education reported less 
trust in physicians as compared to parents with above a high school education (p 
0.05). Hispanic parents were less likely to trust in their physicians and had more
decisional conﬂ icts than White parents (p  0.05). Parents with lower level of consci-
entiousness, emotional stability and openness to experiences were associated with less
trust in physicians and more decisional conﬂ icts as compared to their counterparts
(p  0.05). Parents’ age and children’s health status were not signiﬁ cant factors of 
physician trust and decisional conﬂ icts (p  0.05). Parents’ trust in physicians were 
signiﬁ cantly related to conﬂ icts in the decision-making process (p  0.05). CONCLU-
SIONS: For children with life-limiting conditions, parents who were minority, less 
educated, and with negative personality traits reported less trust in physicians and
more conﬂ icts in the decision making process. Trust plays a signiﬁ cant role in parents’ 
treatment decision making beyond the inﬂ uence of parents’ characteristics.
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OBJECTIVES: The aim of this study was to identify the oncologic patients’ (non
hodgkin lymphoma, breast and colorectal cancer) satisfaction grade with the medical 
care in a tertiary referral center at the Social Security Mexican Institute (IMSS). 
METHODS: A cross-sectional and descriptive study was performed within a tertiary
referral center in Guadalajara City, Mexico. Were included oncologic patients with
non hodgkin lymphoma, breast and colorectal cancer attended as outpatients since
July to August 2008. Was performed an interview with EORTC IN-PATSAT32 in 
Spanish version, this instrument contents 32 items with Likert-like scale answers (1–5) 
to evaluate follow assumptions: medical care, nurse care, other personal care, waiting
time, access facilities to hospital, information exchange, cleaning, comfort and general 
satisfaction (scale 1 to 100). Internal consistency was evaluated through Cronbach’s
alpha test. This questionnaire was previously validated to Mexico. ANOVA was used 
to identify differences between clinical stages and each disease. Statistical analysis was
realized in SPSS 13.0. RESULTS: This study included 157 patients with breast cancer,
30 colorectal cancers and 14 non hodgkin lymphoma. Mean of satisfaction inter-item
was 75 o 18 (20–100), in patients with breast cancer, satisfaction level was 75 o 18, 
non-hodgkin lymphoma 85 o 13 and colorectal cancer 75 o 19, without statistical
difference between diseases (p  0.14). The items with lowest score were cleaning (52
o 34), and other personal care (68 o 27). The highest score were nurse care (86 o 21), 
speciﬁ cally non hodgkin lymphoma group (94 o 14). CONCLUSIONS: The oncologic 
patients’ (non hodgkin lymphoma, breast and colorectal cancer) group was satisﬁ ed 
with the medical care, particularly with the nurses group.
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OBJECTIVES: According to the National Cancer Institute (INCA 2008), breast cancer
(BC) is the malignant neoplasia which more affects Brazilian women (estimated 49,400 
cases, with a crude incidence rate of 50.71 cases per 100 thousand women). Moreover, 
Health Ministry data shows that the mortality rate of the disease is increasing, in
contrast developed countries, such as US (New England Journal of Medicine, 2005).
This mortality may be partially explained by the advanced stages of the disease at
diagnosis (III and IV), which represent 50% of new identiﬁ ed cases in Brazil (INCA
2005). This may be a result of population low awareness of BC and the importance
of early detection. Thus, the objective of this study is to assess women’s knowledge 
of this neoplasia, their perception of its risks and methods of diagnosis. METHODS:
Quantitative study performed through personal and individual interviews. A represen-
tative sample of the population (N  552) was used, composed by women between
30 and 60 year-old living in 4 capitals of Brazil (Rio de Janeiro, Sao Paulo, Porto
Alegre and Salvador). A 20-question structured questionnaire was applied. RESULTS:
Ninety percent of interviewed women understand cancer as a disease that brings health 
risks, highlighting breast (79%) as the most threatening cancer. The majority pointed
out self breast examination (82%) as the best diagnostic method for BC early detec-
tion, followed by mammography (35%). The main information sources of this neo-
plasia, which were spontaneously mentioned were: television shows (80%), hospitals 
(28%), and newspapers (22%). CONCLUSIONS: 79% of all Brazilian women are
aware of the threat BC means to their health, but only some of them see mammogra-
phy (35%) as a method that most importantly can increase the chance of an early
diagnosis. These results will support informative continuous campaigns about the
importance of early detection aiming to give population a greater chance of cure.
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OBJECTIVES: We explored oncologists’ attitudes toward the costs and cost effective-
ness of cancer drugs and their views on various reimbursement policies in the United 
States. METHODS: We surveyed 1379 oncologists based in the United States, selected 
from the American Society of Clinical Oncology (ASCO) membership list. Self-admin-
istered surveys were disseminated by mail between January and August 2008. The 
survey covered the degree to which oncologists believe that treatment costs and 
patients’ out-of-pocket spending inﬂ uence their prescribing behavior. We also asked 
whether the oncologists discuss costs with patients and about the potential use of 
comparative effectiveness and cost effectiveness information. RESULTS: A total of 
787 oncologists responded (response rate 57%). Sixty-seven percent of respondents 
stated that every U.S. patient should have access to effective cancer treatment regard-
less of cost; however, 56% stated that costs inﬂ uenced their decisions about which 
cancer treatments to recommend, and 84% agreed that patient out-of-pocket costs 
inﬂ uenced decisions. Only 42% said they always or frequently discussed cost issues 
with patients. A majority (80%) supported more use of cost effectiveness data in
coverage and payment decisions; only 41% felt well prepared to interpret and use
such information. Respondents leaned toward more government intervention: 57% 
agreed that government price controls for cancer drugs for Medicare were needed; 
79% favored more government research on the comparative effectiveness of cancer 
drugs. After adjusting for other factors, older MDs were more likely to be inﬂ uenced 
by cost and more likely to discuss costs with patients. CONCLUSIONS: Oncologists 
believe that costs inﬂ uence their prescribing, yet relatively few report discussing costs 
frequently with patients. The results highlight the need to educate physicians about 
treatment costs and cost effectiveness and to develop better communication strategies.
They also support research on the comparative effectiveness and cost-effectiveness of 
cancer therapies.
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OBJECTIVES: Cancer and muscular-skeletal diseases are embraced in the group of 
diseases requesting a high number of the health care resources, imposing a substantial 
economic burden to patient, health-social insurance and to society in Slovakia. The 
objective of the study was to estimate the number of productivity lost days and cal-
culate the indirect costs associated with the consumption of the health-social insurance 
system. METHODS: With the use of a national database of patients we developed a
retrospective analysis with the identiﬁ cation of the number of productivity lost days 
due to cancer and muscular-skeletal disorders during the period of the year 2007. By 
the comparison-analysis we analyzed the differences between the longest and the
shortest period of productivity lost focusing on the cancer and muscular-skeletal and
we calculated the health-social insurance costs. RESULTS: Cancer shows the average 
number of productivity lost in males 104.2 and 74.3 in females, the longest period of 
days of productivity lost represent 151.4 days in males age 60 and more and 119.7
days in females age 55–59. Muscular-skeletal diseases showed these results: in average 
41.2 days in males and 50.3 days in females. The longest period of days of productivity
lost, is 64.4 days in males age 55–59, and 76.9 days in females age 60. One day of 
productivity lost costs the health-social insurance system in average €140.78 per 
patient, in this case, days of lost productivity due to cancer represent the average costs
of health insurance €25.129,23 and due to the muscular-skeletal €12.881,37; in both 
gender together. This number represents indirect costs. CONCLUSIONS: This retro-
spective analysis highlighted the importance to pay attention to indirect cost during 
the overall management of decision-making process for the cancer and muscular-
skeletal diseases due to their high supplies of health resources.
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OBJECTIVES: Little information is available about physician visit and referral
patterns among patients diagnosed with Stage IV PCa. The objective of this study 
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is to characterize patient referrals between urologists and medical oncologists/
hematologists (MOH) following diagnosis of Stage IV disease. METHODS: A retro-
spective analysis of linked Surveillance, Epidemiology, and Endpoints (SEER) – 
Medicare data included patients diagnosed with Stage IV PCa between 1994 and 2002 
(age  65 years). Patients who saw a MOH before the urologist visit were deleted. 
Patients were grouped according to M0/M1 substage. Time to physician visit, in
months (m), was deﬁ ned relative to diagnosis in the base case. RESULTS: Application
of the inclusion and exclusion criteria resulted in 8840 patients (average age 77 years;
81% White; 68% M1 disease). Seventy-four percent of the patients visited a urologist. 
Of these, 33% followed up with a MOH. Of these, 41.5% saw the MOH within 6 m, 
55.7% within 12 m, and 25% waited 24 m. The mean time to MOH visit was 
longer when a patient saw a urologist ﬁ rst, compared to when a patient did not see
a urologist (20.1 m vs. 5.2 m; p  0.0001). M1 patients saw MOH sooner than M0 
patients: 14.1 m vs. 27.5 m; p  0.0001. Qualitative results were similar whether
conditioned for a urologist visit (16.9 m vs. 29 m; p  0.0001) or conditioned for ‘no 
urologist visit’ (4.6 m vs. 11.1 m; p  0.01). CONCLUSIONS: Similar to other studies,
we ﬁ nd that the majority of patients with Stage IV PCa see a urologist post diagnosis.
About a third of patients who see a urologist are referred to a MOH and 25% 
wait more than 2 years to see the MOH. We ﬁ nd that the time to a MOH visit aver-
ages 20 months among those who ﬁ rst see a urologist versus 5 months among those 
who do not.
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OBJECTIVES: To examine epoetin alfa (EPO) and darbepoetin alfa (DARB) drug 
utilization in cancer chemotherapy patients before and after ESA coverage limitations
by the Centers for Medicare and Medicaid Services National Coverage Determination
(NCD). METHODS: Medical claims from the Ingenix Impact National Managed Care
Database were analyzed. Patients included in the study were q18 years, had q1 claim
for cancer, were newly initiated on EPO or DARB, and received chemotherapy during 
ESA treatment. Patients initiating ESA therapy between 8/2006–12/2006 (pre-NCD) 
were compared with those initiating between August 2007–December 2007 (post-
NCD). The number of patients treated, dose per injection, cumulative drug utilization
during the ﬁ rst 16 weeks of therapy, and dose ratio (cumulative dose EPO: DARB) 
were compared between the two groups. RESULTS: A total of 3951 ESA treatment 
episodes were identiﬁ ed (pre-NCD: 3046; post-NCD: 905). Patients in the post-NCD 
group were generally older (pre-NCD: 56.2 years; post-NCD: 58.7 years; p  0.0001) 
than the pre-NCD group. The number of patients receiving ESA in the post-NCD 
relative to pre-NCD period decreased by 61% (from 1057 to 411 patients) for EPO 
and 75% (from 1989 to 494 patients) for DARB. Furthermore, among the subset of 
treated patients in each period, total dose administered per patient within 16 weeks 
of treatment initiation decreased by 20% (Units: pre-NCD 251,902 vs. post-NCD 
200,635) for EPO and 13% (mcg: pre-NCD 917 vs post-NCD 801) for DARB, despite 
stable dose per injection pre- and post-NCD. The EPO: DARB dose ratio was higher 
in the pre-NCD group (274:1) than the post-NCD group (250:1). CONCLUSIONS:
Recent changes to ESA coverage policy appear to have decreased ESA utilization and 
the corresponding EPO: DARB dose ratio. Further research is warranted to assess this
impact on the demand for blood transfusions.
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OBJECTIVES: More and more evidences support the granulocyte-colony stimulating 
factor (G-CSF) use as a primary prophylaxis in breast cancer patients treated with 
high risk of febrile neutropenia(FN). Although National Comprehensive Cancer
Network have the practice guidance, Bureau of National Insurance in Taiwan doesn’t
approve the claim for the indication. The aim of this study was to evaluate the effec-
tiveness of G-CSF for preventive treatment of FN. METHODS: The retrospective 
study was conducted from January 1, 2001 to December 31, 2006. Breast cancer 
patients treated with taxanes-based regimens simultaneously combined with primary 
prophylactic G-CSF were recruited in this study. The three regimens were TEC, FECP
and TE (C, cyclophosphamide; E, epirubicin; F, ﬂ uorouracil; P, paclitaxel; T, docetaxel).
ANOVA and Chi-square were used to analyze the relationship of the decline of inci-
dence of FN by using primary G-CSF prophylaxis between diferent regimens.
RESULTS: Finally,128 patients were eligible in the study. The results show the baseline 
laboratory data of breast cancer patients in TEC group is in normal range compared
to others. However, the laboratory data of TEC group appeared worse than others 
after G-CSF was given at the dose of 5 mg/kg. Under the primary prophylactic G-CSF
policy, the incidence of FN in TEC group was higher than TE groups (4.7% versus 
0.6%), but no FN appeared in FECP regimen. It showed that TEC regimen have 
more bone-marrow suppression effect than others. Our ﬁ nding also indicated a better
results decrease FN by using G-CSF as a prophylaxis as compared to other published 
studies.(episodes of FN in our study were lower than published  2.4% versus 7.5%) 
CONCLUSIONS: The study showed the beneﬁ cial effect of declining the occurrence 
of FN. We hope that the use of primary prophylactic G-CSF should be considered as 
a guideline for clinical practice to improve patient’s quality of life.
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OBJECTIVES: This study evaluated the use of breast cancer (BC) screening or diag-
nostic procedures in postmenopausal women (PMW) initiating osteoporosis (OP) 
medications. METHODS: Women 50 years and older with at least one claim for ral-
oxifene (RLX), bisphosphonates (BIS) or calcitonin (CT) in 2005 or 2006 and continu-
ous enrollment in the previous and subsequent 12 months were identiﬁ ed in a large 
national commercial and Medicare claims database. PMW initiating RLX were com-
pared to PMW initiating BIS and CT in terms of BC screening or diagnostic procedures 
(mammogram, breast MRI, ultrasound, breast biopsy) as well as age, provider spe-
cialty, fractures, BMD screening and comorbidities. RESULTS: Treatment-naive PMW 
aged 55–59 years were more likely to initiate RLX than other age groups (Adjusted
Odds Ratio (AOR)  1.864 vs. aged 70 years; p  0.0001). RLX patients were 
younger than BIS and CT patients (mean age 63 years [RLX], 66 years [BIS], 72 years
[CT]; p  0.05). Treatment-naive PMW with at least one BC screening or diagnostic 
claim within the 12 month pre-period were more likely to initiate on RLX than those 
with none during the same period (AOR  1.183, p  0.0001). Treatment-naïve RLX 
patients were more likely to have had BC screening or diagnostic procedures in the 
12 months prior to therapy initiation than treatment-naïve BIS or CT patients (RLX 
61%, BIS 57%, CT 41%; p  0.05) and were more likely to have an increased fre-
quency of mammograms in the 12 months after therapy initiation (RLX 18%, BIS
16%, CT 15%, p  0.05). CONCLUSIONS: In this study population, PMW who 
initiated RLX treatment were more likely to have had BC screening or diagnostic 
procedures prior to initiating therapy than PMW on other OP medications. This data
suggests that PMW who initiate on RLX may have greater perceived or actual risks
for BC than PMW who initiate on other therapies.
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OBJECTIVES: Preoperative or postoperative radiotherapy has been used to decrease 
local recurrence and thereby improve survival. Previous studies comparing these two 
types of treatments have given conﬂ icting results. The study aims to compare the efﬁ -
ciency of preoperative versus postoperative radiotherapy in terms of survival for 
resectable colorectal cancer (Stage II and III). METHODS: The study has been carried
out on patients with resectable colorectal cancer in stage II and III. It is based on the
data recorded by National Cancer institute, Surveillance Epidemiology and End
Results (SEER) 17 registries data between year 1999 and 2005. Survival analysis was 
used to assess the patients exposed to radiotherapy as an adjuvant therapy before or
after surgery and a comparison of survival time in between the two groups was done 
using the log rank test. RESULTS: A total of 12,134 patients were subjected to radio-
therapy as adjuvant therapy. Out of which 7481 were administered with radiation 
after surgery and 4653 patients with radiation prior to surgery were taken into con-
sideration for the study. Patients who have been administered radiotherapy after 
surgery have shown longer survival time (43 months) than patients administered with
radiotherapy before surgery (33 months) (p  0.000). The survival time difference may
also be attributable to the Stage of the cancer. The survival time for Stage III patients 
receiving radiation after surgery is longer than patients administered with radiation 
before surgery (43 months vs. 29 months; p  0.000). No signiﬁ cant survival difference 
was observed in Stage II patients. CONCLUSIONS: The study should assist the clini-
cian in forming a preliminary opinion for further investigations pertaining to the 
sequence of radiation with surgery as adjuvant therapy for resectable colorectal cancer. 
Further studies should also investigate the inﬂ uence of demographics, dose of radiation
and co-morbidity on survival time in the resectable colorectal cancer cases.
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OBJECTIVES: Screening mammography is regarded as the gold standard for identify-
ing breast cancer in early stages. The American Cancer Society (ACS) recommends
annual screening mammography for all women q40 years of age with an average risk
of breast cancer for early cancer detection. Mammography rates generally tend to be 
lower among indigent women. The purpose of this study was to determine annual 
mammography screening trends from 2000 to 2005 among fee-for-service women 
recipients enrolled in a state Medicaid program based on demographic and geographic 
characteristics. METHODS: Fee-for-service medical claims for all women enrolled in 
the state Medicaid program from January 1, 2000 to December 31, 2005 were used.
